Summary
This 8-K filing from Johnson & Johnson (JNJ) addresses a significant legal development concerning talc litigation. The company announced that the United States Supreme Court denied its petition to review the "Ingham verdict," which had previously reduced a jury award from $4.7 billion to $2.1 billion. This denial means the $2.1 billion judgment, adjusted for accrued interest, will be paid out by the company in June 2021, totaling approximately $2.5 billion.
Key Highlights
- 1US Supreme Court denied JNJ's petition to review the Ingham talc verdict.
- 2The original $4.7 billion verdict was previously reduced to $2.1 billion by the Missouri Court of Appeals.
- 3JNJ will make a payment of approximately $2.5 billion in June 2021, including accrued interest.
- 4This payment is a result of the Missouri Supreme Court's earlier decision not to hear the company's appeal.
- 5The company had already recorded a reserve consistent with the reduced Ingham verdict in its 2020 fiscal year-end results.
Frequently Asked Questions
The "Ingham verdict" refers to a legal case involving talc products. Initially, a jury awarded $4.7 billion in damages. This amount was later reduced to $2.1 billion by the Missouri Court of Appeals. The recent denial by the US Supreme Court to hear JNJ's appeal makes this reduced judgment final and requires JNJ to pay a substantial sum.
Johnson & Johnson will make a payment of approximately $2.5 billion, which includes the $2.1 billion judgment plus total accrued interest. This payment is scheduled to be made in June 2021.
Yes, Johnson & Johnson recorded a reserve consistent with the reduced Ingham verdict amount in its 2020 fiscal year-end results. Therefore, the financial impact of this payment has already been reflected in the company's past financial statements.
The denial by the US Supreme Court means that the company has exhausted its legal options to overturn or further reduce the $2.1 billion judgment (plus interest). The payment of approximately $2.5 billion is now definitive.